Published in PLoS One on August 06, 2012
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res (2013) 1.23
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res (2013) 1.20
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia (2014) 1.17
Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT (2013) 1.14
Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene (2014) 1.11
Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling. Oncotarget (2014) 0.99
Bone marrow endothelium-targeted therapeutics for metastatic breast cancer. J Control Release (2014) 0.96
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Res (2013) 0.94
Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep (2015) 0.91
Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol (2013) 0.90
A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype. Breast Cancer Res (2013) 0.89
Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells. PLoS One (2013) 0.89
Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta (2015) 0.88
Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation. Cancer Res (2013) 0.86
Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. BMC Cancer (2013) 0.85
STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J (2015) 0.84
Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget (2015) 0.82
Targeting SH2 domains in breast cancer. Future Med Chem (2014) 0.82
Design and in vitro evaluation of layer by layer siRNA nanovectors targeting breast tumor initiating cells. PLoS One (2014) 0.80
AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. Oncotarget (2014) 0.79
An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures". J Comput Aided Mol Des (2015) 0.78
STAT3 activation and risk of recurrence in meningiomas. Oncol Lett (2017) 0.75
Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget (2016) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature (1998) 5.04
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Stem cells in normal breast development and breast cancer. Cell Prolif (2003) 4.47
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 3.96
STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 3.75
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther (2010) 2.00
Complex roles of Stat1 in regulating gene expression. Oncogene (2000) 1.87
Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat (2009) 1.77
Estrogen-receptor-alpha exchange and chromatin dynamics are ligand- and domain-dependent. J Cell Sci (2006) 1.72
STAT3: a critical transcription activator in angiogenesis. Med Res Rev (2008) 1.69
Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev (2005) 1.65
Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One (2009) 1.37
G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res (2004) 1.29
STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int J Cancer (2011) 1.19
Targeting transcription factors for cancer therapy. Curr Pharm Des (2005) 1.10
Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. J Biol Chem (2007) 1.08
Protein tyrosine phosphatases, TC-PTP, SHP1, and SHP2, cooperate in rapid dephosphorylation of Stat3 in keratinocytes following UVB irradiation. PLoS One (2010) 1.03
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth (2009) 8.28
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Extracellular histones are major mediators of death in sepsis. Nat Med (2009) 6.55
Cancer proliferation gene discovery through functional genomics. Science (2008) 5.41
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 5.40
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A (2003) 4.69
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol (2008) 4.30
TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature (2007) 4.23
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol (2005) 3.62
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res (2008) 3.45
Aurora B phosphorylates spatially distinct targets to differentially regulate the kinetochore-microtubule interface. Mol Cell (2010) 3.44
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A (2011) 3.40
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell (2011) 3.27
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development (2007) 3.07
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol (2010) 2.93
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. Nature (2013) 2.52
Research with stored biological samples: what do research participants want? Arch Intern Med (2005) 2.43
Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res (2007) 2.30
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol (2006) 2.24
Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg (2008) 2.14
Targeting Stat3 in cancer therapy. Anticancer Drugs (2005) 2.13
An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12
Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis (2005) 2.11
Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol (2011) 2.09
Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun (2003) 2.05
A critical role for TPP1 and TIN2 interaction in high-order telomeric complex assembly. Proc Natl Acad Sci U S A (2006) 2.04
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 2.01
Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.00
Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res (2012) 2.00
Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells (2008) 1.96
Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem (2008) 1.96
CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell (2008) 1.94
Whole-genome sequencing of cultivated and wild peppers provides insights into Capsicum domestication and specialization. Proc Natl Acad Sci U S A (2014) 1.91
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
Irgm1 protects hematopoietic stem cells by negative regulation of IFN signaling. Blood (2011) 1.86
Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat (2005) 1.85
Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. J Natl Cancer Inst (2011) 1.84
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol (2013) 1.81
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res (2013) 1.80
The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res (2007) 1.79
Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res (2010) 1.77
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res (2008) 1.75
EUS elastography for diagnosis of solid pancreatic masses: a meta-analysis. Gastrointest Endosc (2012) 1.74
Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res (2003) 1.73
Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the Fsr system of Enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol (2006) 1.71
Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood (2011) 1.69
Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res (2012) 1.68
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res (2006) 1.67
Influenza H7N9 and H9N2 viruses: coexistence in poultry linked to human H7N9 infection and genome characteristics. J Virol (2014) 1.67
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res (2004) 1.67
Medical complications and outcomes after hip fracture repair. Arch Intern Med (2002) 1.65
Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation. J Cell Biol (2009) 1.65
Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A (2006) 1.60
Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology (2005) 1.59
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol (2005) 1.58
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One (2011) 1.57
The telosome/shelterin complex and its functions. Genome Biol (2008) 1.57
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res (2011) 1.56
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res (2011) 1.54
OB fold-containing protein 1 (OBFC1), a human homolog of yeast Stn1, associates with TPP1 and is implicated in telomere length regulation. J Biol Chem (2009) 1.53